Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Kelaidi · SciRah

Researcher profile · Semantic Scholar

C. Kelaidi

Share profile

C. Kelaidi — researcher profile on SciRah

h-index: 21
Works: 103
Citations: 1,924

Most-cited papers

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.
Sophie Park, S. Grabar, C. Kelaidi, O. Beyne-Rauzy +21 more
2008Blood331 citations Open access
Semantic Scholar
Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study
U. Germing, Michael Lauseker, B. Hildebrandt, A. Symeonidis +28 more
2012Leukemia133 citations Open access
Semantic Scholar
Monogenic early-onset lymphoproliferation and autoimmunity: Natural history of STAT3 gain-of-function syndrome
J. Leiding, T. Vogel, Valentine G.J. Santarlas, R. Mhaskar +222 more
2022Journal of Allergy and Clinical Immunology100 citations Open access
Semantic Scholar
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Sophie Park, J. Hamel, A. Toma, C. Kelaidi +36 more
2017Journal of Clinical Oncology95 citations Open access
Semantic Scholar
Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.
C. Kelaidi, S. Chevret, S. de Botton, E. Raffoux +16 more
2009Journal of Clinical Oncology85 citations
Semantic Scholar
Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide.
C. Kelaidi, Sophie Park, S. Bréchignac, L. Mannone +15 more
2008Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis82 citations
Semantic Scholar
Treatment with bortezomib‐based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group
E. Katodritou, E. Terpos, C. Kelaidi, M. Kotsopoulou +13 more
2014American journal of hematology/oncology69 citations Open access
Semantic Scholar
Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents
C. Kelaidi, Sophie Park, R. Sapena, O. Beyne-Rauzy +16 more
2013Leukemia67 citations Open access
Semantic Scholar
Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients.
Sophie Park, C. Kelaidi, R. Sapena, D. Vassilieff +13 more
2010Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis63 citations
Semantic Scholar
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients
E. Katodritou, E. Terpos, A. Symeonidis, A. Pouli +22 more
2014American journal of hematology/oncology57 citations Open access
Semantic Scholar
Gain-of-function mutations in RPA1 cause a syndrome with short telomeres and somatic genetic rescue
Richa Sharma, S. Sahoo, Masayoshi Honda, Sophie L. Granger +29 more
2021Blood56 citations Open access
Semantic Scholar
High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM
C. Kelaidi, O. Beyne-Rauzy, T. Braun, R. Sapena +22 more
2013Annals of Hematology50 citations
Semantic Scholar
Measurable Residual Disease and Fusion Partner Independently Predict Survival and Relapse Risk in Childhood KMT2A-Rearranged Acute Myeloid Leukemia: A Study by the International Berlin-Frankfurt-Münster Study Group
Romy E. van Weelderen, K. Klein, C. Harrison, Yi-Li Jiang +29 more
2023Journal of Clinical Oncology49 citations Open access
Semantic Scholar
Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies
L. Adès, F. Le Bras, M. Sébert, C. Kelaidi +16 more
2012Haematologica43 citations Open access
Semantic Scholar
Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.
F. Le Bras, M. Sébert, C. Kelaidi, T. Lamy +16 more
2011Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis41 citations
Semantic Scholar
lyl-1 and tal-1/scl, two genes encoding closely related bHLH transcription factors, display highly overlapping expression patterns during cardiovascular and hematopoietic ontogeny.
S. Giroux, Anna-Lila Kaushik, C. Capron, Ali Q. Jalil +5 more
2007Gene Expression Patterns37 citations
Semantic Scholar
Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia
Romy E. van Weelderen, C. Harrison, K. Klein, Yi-Li Jiang +31 more
2024Blood Advances30 citations Open access
Semantic Scholar
The role of lenalidomide in the management of myelodysplasia with del 5q
C. Kelaidi, V. Eclache, P. Fenaux
2008British Journal of Haematology30 citations
Semantic Scholar
Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS.
Sophie Park, R. Sapena, C. Kelaidi, D. Vassilieff +12 more
2011Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis26 citations
Semantic Scholar
Integrative Genomic Analysis of Pediatric Myeloid-Related Acute Leukemias Identifies Novel Subtypes and Prognostic Indicators
M. Fornerod, Jing Ma, Sanne Noort, Yu Liu +30 more
2021Blood Cancer Discovery25 citations Open access
Semantic Scholar
Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials)
C. Kelaidi, L. Adès, S. Chevret, M. Sanz +16 more
2006Leukemia21 citations
Semantic Scholar
The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion
Sophie Park, C. Kelaidi, Mathieu Meunier, N. Casadevall +2 more
2019Annals of Hematology20 citations Open access
Semantic Scholar
Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myélodysplasies
C. Kelaidi, A. Stamatoullas, O. Beyne-Rauzy, E. Raffoux +16 more
2010Haematologica19 citations Open access
Semantic Scholar
Analysis of rare driving events in pediatric acute myeloid leukemia
Sanne Noort, J. V. van Oosterwijk, Jing Ma, Elizabeth A. R. Garfinkle +15 more
2022Haematologica17 citations Open access
Semantic Scholar
Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
T. Prebet, T. Cluzeau, Sophie Park, M. Sekeres +13 more
2017OncoTarget16 citations Open access
Semantic Scholar
PML–RARα ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL
E. Schachter-Tokarz, C. Kelaidi, B. Cassinat, C. Chomienne +5 more
2010Leukemia15 citations
Semantic Scholar
Mediterranean Journal of Hematology and Infectious Diseases Treatment of Acute Promyelocytic Leukemia
C. Kelaidi, L. Adès, P. Fenaux
201114 citations
Semantic Scholar
Bone Marrow Failure in Fanconi Anemia: Clinical and Genetic Spectrum in a Cohort of 20 Pediatric Patients
C. Kelaidi, A. Makis, L. Petrikkos, Kondilia Antoniadi +8 more
2019Journal of pediatric hematology/oncology13 citations
Semantic Scholar
Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond
C. Kelaidi, P. Fenaux
2010Expert Opinion on Biological Therapy13 citations
Semantic Scholar
Treatment of the 5q- syndrome.
P. Fenaux, C. Kelaidi
2006Hematology. American Society of Hematology. Education Program13 citations Open access
Semantic Scholar
PlGF and sFlt‐1 levels in patients with non‐transfusion‐dependent thalassemia: Correlations with markers of iron burden and endothelial dysfunction
C. Kelaidi, A. Kattamis, F. Apostolakou, C. Poziopoulos +4 more
2018European Journal of Haematology12 citations
Semantic Scholar
Granulocyte colony stimulating factor-induced exacerbation of fungus-related immune restoration inflammatory syndrome: a case of chronic disseminated candidiasis exacerbation.
M. Chandesris, C. Kelaidi, F. Méchaï, M. Bougnoux +6 more
2010Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi11 citations Open access
Semantic Scholar
When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group).
B. Cassinat, S. de Botton, C. Kelaidi, L. Adès +20 more
2009Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis11 citations
Semantic Scholar
Clinical Features, Outcome and Prognostic Factors For Survival and Evolution To Multiple Myeloma Of Solitary Plasmacytomas: A Report Of The Greek Myeloma Study Group In 97 Patients
E. Terpos, A. Symeonidis, A. Pouli, C. Kelaidi +19 more
201310 citations
Semantic Scholar
Prognostic Factors for Cardiotoxicity among Children with Cancer: Definition, Causes, and Diagnosis with Omics Technologies
K. Antoniadi, N. Thomaidis, P. Nihoyannopoulos, K. Toutouzas +3 more
2023Diagnostics8 citations Open access
Semantic Scholar
Specific abnormalities versus number of abnormalities and cytogenetic scoring systems for outcome prediction after allogeneic hematopoietic SCT for myelodysplastic syndromes
C. Kelaidi, I. Tzannou, I. Baltadakis, I. Batsis +11 more
2014Bone Marrow Transplantation8 citations
Semantic Scholar
Adolescents and young adults (AYA) with acute myeloid leukemia (AML): real-world long-term results and age-specific outcomes
C. Lalayanni, C. Demosthenous, Michail Iskas, C. Kelaidi +8 more
2022Leukemia and Lymphoma7 citations
Semantic Scholar
Long‐term outcome, clinical course and treatment approaches of paediatric langerhans cell histiocytosis: A greek reference centre report
Vasiliki Tzotzola, L. Petrikkos, V. Papadakis, G. Mitropoulou +3 more
2020Acta paediatrica7 citations
Semantic Scholar
Loss-of-phosphorylation of IKZF1 results in gain-of-function associated with immune dysregulation.
Akihiro Hoshino, B. H. Picard, Sophia Polychronopoulou, C. Kelaidi +5 more
2024Journal of Allergy and Clinical Immunology6 citations Open access
Semantic Scholar
Outcomes and mutational analysis of patients with lower-risk non-del5q myelodysplastic syndrome treated with antithymocyte globulin with or without ciclosporine A.
C. Kelaidi, T. Braun, R. Arana, Alice Marceau-Renaut +12 more
2018Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis6 citations
Semantic Scholar
Slow relapse in acute myeloid leukemia with inv(16) or t(16;16)
T. Clozel, Aline Renneville, M. Venot, C. Gardin +6 more
2009Haematologica6 citations Open access
Semantic Scholar
Treatment of Lower Risk MDS with Del 5q with Lenalidomide (LEN): Results of the French ATU Program.
F. Le Bras, M. Sébert, C. Kelaidi, T. Lamy +22 more
20096 citations
Semantic Scholar
P135 Has treatment with EPO+/-G-CSF an impact on progression to AML and survival in low/int-1-risk MDS? A comparison between French-EPO patients and the IMRAW database
S. Park, S. Grabar, C. Kelaidi, O. Beyne-Rauzy +19 more
20076 citations
Semantic Scholar
The paradigm of hematological malignant versus non-malignant manifestations, driven by primary immunodeficiencies: a complex interplay
C. Kelaidi, V. Tzotzola, S. Polychronopoulou
2021Familial Cancer5 citations
Semantic Scholar
Risk of AML Evolution In Lower Risk MDS with Del 5q Treated with or without Lenalidomide. A Report by the Groupe Francophone Des Myelodysplasies (GFM)
L. Adès, F. Lebras, M. Sébert, C. Kelaidi +13 more
20105 citations
Semantic Scholar
Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience.
Sophie Park, C. Kelaidi, S. Grabar, O. Beyne-Rauzy +21 more
20065 citations
Semantic Scholar
Outcome of (Novel) Subgroups in 1257 Pediatric Patients with KMT2A-Rearranged Acute Myeloid Leukemia (AML) and the Significance of Minimal Residual Disease (MRD) Status: A Retrospective Study By the I-BFM-SG
Romy E. van Weelderen, K. Klein, B. Goemans, C. Zwaan +27 more
20204 citations
Semantic Scholar
Azacitidine (AZA) After Failure of Lenalidomide (LEN) in Low/Int-1 Risk MDS with Del 5q
C. Bally, R. Itzykson, B. Gruson, D. François +10 more
20114 citations
Semantic Scholar
Myelodysplastic Syndrome (MDS) in France: Results of a One-Week Cross-Sectional Survey on Daily Practice Management in 919 Patients by the GFM
C. Kelaidi, A. Stamatoullas, O. Beyne-Rauzy, F. Dreyfus +22 more
20084 citations
Semantic Scholar
Acute Leukemia in Children with Down Syndrome: A Report from the Hellenic HESPHO Group
Eugenia Papakonstantinou, A. Tragiannidis, Mirella Ampatzidou, Nikolaos Katzilakis +14 more
2025Hemato3 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

P. Fenaux×22
Invite
P. Fenaux — researcher profile on SciRah
L. Adès×16
Invite
L. Adès — researcher profile on SciRah
F. Dreyfus×15
Invite
F. Dreyfus — researcher profile on SciRah
N. Vey×13
Invite
N. Vey — researcher profile on SciRah

×12

Invite

O. Beyne-Rauzy — researcher profile on SciRah

S. Polychronopoulou×11

Invite

S. Polychronopoulou — researcher profile on SciRah

A. Stamatoullas×10

Invite

A. Stamatoullas — researcher profile on SciRah

Invite

A. Guerci — researcher profile on SciRah

Invite

Sophie Park — researcher profile on SciRah

Invite

S. Chéze — researcher profile on SciRah

Invite

H. Dombret — researcher profile on SciRah

S. de Botton×7

Invite

S. de Botton — researcher profile on SciRah